Long noncoding RNAs as putative biomarkers for prostate cancer detection

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer is a leading cause of male mortality in the US.
• Early detection biomarkers are crucial to reduce overtreatment and morbidity.
• Current diagnostic methods require improvement for sensitivity and specificity.

Purpose of the Study:

• To identify and characterize novel long noncoding RNAs (lncRNAs) as potential biomarkers for early prostate cancer detection.
• To evaluate the expression of specific lncRNAs in prostate cancer tissues and urine samples.
• To investigate the functional role of a specific lncRNA (SPRY4-IT1) in prostate cancer progression.

Main Methods:

• Differential expression analysis of lncRNAs in prostate cancer cell lines and patient tissues.
• Quantification of six selected lncRNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, XLOC_009911) in tumor and matched normal tissues.
• Detection and comparison of lncRNA levels in patient urine samples versus healthy controls.
• Functional studies using siRNA knockdown of SPRY4-IT1 in PC3 prostate cancer cells.
• Development of a chromogenic in situ hybridization (CISH) assay for lncRNA detection.

Main Results:

• Six lncRNAs were identified as differentially expressed in prostate adenocarcinoma.
• These lncRNAs were successfully detected and found to be upregulated in urine samples from prostate cancer patients compared to healthy individuals.
• SPRY4-IT1 (AK024556) was significantly upregulated in PC3 cells, and its knockdown inhibited proliferation and invasion while increasing apoptosis.
• A CISH assay was developed for lncRNA detection in tissue samples.

Conclusions:

• The identified lncRNAs show promise as non-invasive biomarkers for early prostate cancer detection in urine.
• SPRY4-IT1 plays a functional role in prostate cancer cell behavior, suggesting its involvement in tumorigenesis.
• The developed CISH assay provides a basis for clinical diagnostic applications.
• Further studies are warranted to validate these lncRNAs for distinguishing benign from precancerous prostate lesions.